{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:35:48Z","timestamp":1783485348135,"version":"3.55.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000149","name":"Canadian Association of Gastroenterology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000149","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009560","name":"American Gastroenterological Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009560","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.bpg.2019.03.002","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T12:25:01Z","timestamp":1551875101000},"page":"101606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Pharmacology, efficacy and safety of JAK inhibitors in Crohn\u2019s disease"],"prefix":"10.1016","volume":"38-39","author":[{"given":"Christopher","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Vande Casteele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2019.03.002_bib1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"key":"10.1016\/j.bpg.2019.03.002_bib2","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bpg.2019.03.002_bib3","doi-asserted-by":"crossref","first-page":"16777","DOI":"10.1074\/jbc.M207999200","article-title":"Constitutive STAT3 activation in intestinal T cells from patients with Crohn\u2019s disease","volume":"278","author":"Lovato","year":"2003","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.bpg.2019.03.002_bib4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/gut.51.3.379","article-title":"Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease","volume":"51","author":"Schreiber","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.03.002_bib5","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bpg.2019.03.002_bib6","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bcp.13523","article-title":"Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: results from a dose-ranging phase 2 trial","volume":"84","author":"Mukherjee","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bpg.2019.03.002_bib7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bpg.2019.03.002_bib8","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A\u00a0phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.03.002_bib9","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Panes","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.03.002_bib10","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1093\/ibd\/izy037.024","article-title":"Post-hoc analysis of tofacitinib crohn\u2019s disease phase 2 induction efficacy in subgroups with baseline endoscopic or biomarker evidence of inflammation","volume":"24","author":"Sands","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.bpg.2019.03.002_bib11","article-title":"Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy volunteers and rheumatoid arthritis patients","volume":"65","author":"Galien","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpg.2019.03.002_bib12","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpg.2019.03.002_bib13","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bpg.2019.03.002_bib14","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.03.002_bib15","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bpg.2019.03.002_bib16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.03.002_bib17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/annrheumdis-2014-eular.3823","article-title":"THU0127 Pharmacodynamics of A Novel JAK1 selective inhibitor in rat arthritis and anemia models and in healthy human subjects","volume":"73","author":"Voss","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bpg.2019.03.002_bib18","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s40262-016-0419-y","article-title":"Pharmacokinetics, safety and tolerability of ABT-494, a novel selective JAK 1 inhibitor, in healthy volunteers and subjects with rheumatoid arthritis","volume":"55","author":"Mohamed","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.bpg.2019.03.002_bib19","doi-asserted-by":"crossref","first-page":"S1308","DOI":"10.1016\/S0016-5085(17)34357-3","article-title":"Safety and efficacy of ABT-494 (upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with crohn\u2019s disease: results from celest","volume":"152","author":"Sandborn","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.03.002_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(18)31008-4","article-title":"Efficacy and safety of upadacitinib maintenance treatment for moderate to severe crohn\u2019s disease: results from the celest study","volume":"154","author":"Panes","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.03.002_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/S0016-5085(18)31582-8","article-title":"Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with crohn\u2019s disease: data from the celest study","volume":"154","author":"Panaccione","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.03.002_bib22","article-title":"Improvement in patient-reported outcomes with upadacitinib in patients with moderately to severely active crohn\u2019s disease: 52-week data from the celest study","volume":"6","author":"Peyrin-Biroulet","year":"2018","journal-title":"United European Gastroenterol J."},{"key":"10.1016\/j.bpg.2019.03.002_bib23","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/apt.14449","article-title":"Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis","volume":"47","author":"Bonovas","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.03.002_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/apt.14422","article-title":"Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis","volume":"47","author":"Singh","year":"2018","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691819300095?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691819300095?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:02:26Z","timestamp":1761498146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691819300095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":24,"alternative-id":["S1521691819300095"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2019.03.002","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology, efficacy and safety of JAK inhibitors in Crohn\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2019.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101606"}}